Organisms | Evidence |
---|---|
Staphylococcus aureus |
RES 1r:r1 REP REP1:6o(3+1)2d=-1--1 RES 2b:b-dgal-HEX-1:5|6:d 3s:n-acetyl 4b:a-lgal-HEX-1:5|6:d 5s:n-acetyl 6b:b-dman-HEX-1:5|6:a 7s:n-acetyl 8s:acetyl LIN 1:2d(2+1)3n 2:2o(3+1)4d 3:4d(2+1)5n 4:4o(3+1)6d 5:6d(2+1)7n 6:6o(4+1)8n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
16087046 | NMR assays for carbohydrate-based vaccines | Jones C | 2005 Aug 10 |
|
15040941 | Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials | Fattom AI | 2004 Feb 17 |
|
8606192 | Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus | Sau S | 1996 Apr |
|
805001 | Lymphocyte-mediated cytotoxicity against tumor cells. I. Con A activated cytotoxic effector cells exhibit immunological specificity | Waterfield JD | 1975 Jun |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025